Applied Therapeutics Past Performance

Past criteria checks 0/6

Applied Therapeutics's earnings have been declining at an average annual rate of -25.8%, while the Biotechs industry saw earnings growing at 32.1% annually. Revenues have been growing at an average rate of 171.3% per year.

Key information

-25.8%

Earnings growth rate

4.4%

EPS growth rate

Biotechs Industry Growth	32.1%
Revenue growth rate	171.3%
Return on equity	n/a
Net Margin	-652.2%
Last Earnings Update	31 Mar 2023

Recent past performance updates

Recent updates

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

May 19

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Jan 19

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Nov 11

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Aug 13

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

Jun 17

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

May 15

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Feb 26

Earnings and Revenue History

Quality Earnings: APLT is currently unprofitable.

Growing Profit Margin: APLT is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: APLT is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.

Accelerating Growth: Unable to compare APLT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).

Return on Equity

High ROE: APLT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Strong past performing companies in the Pharmaceuticals & Biotech industry.

Applied Therapeutics Past Performance

Past criteria checks 0/6

Key information

Recent past performance updates

New 90-day low: US$18.92

New 90-day high: US$25.41

New 90-day low: US$18.18

New 90-day low: US$22.43

New 90-day low - US$24.69

Recent updates

Consensus revenue estimates increase by 89%

Consensus revenue estimates increase by 1,731%

Applied Therapeutics Announces Positive Sorbitol Reduction Data from the Ongoing Phase 3 Inspire Trial in Sorbitol Dehydrogenase (Sord) Deficiency

Price target increased by 27% to US$15.00

Insufficient new directors

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

Applied Therapeutics, Inc. Announces Positive Data Trend in AT-007 Action-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

Price target increased to US$16.50

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell 2000 Growth Index

Applied Therapeutics Receives Orphan Medicinal Product Designation from the Ema for AT-007 for Treatment of Galactosemia

Insufficient new directors

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

Price target decreased to US$12.10

Applied Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$13.63

Price target decreased to US$28.80

Applied Therapeutics, Inc. Announces Executive Changes

Applied Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

Price target increased to US$39.20

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

Applied Therapeutics, Inc Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

Price target decreased to US$34.40

Price target increased to US$49.40

Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?

Chair of the Board of Directors recently bought US$145k worth of stock

Chief Medical Officer notifies of intention to sell stock

Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation

Chief Medical Officer exercised options and sold US$714k worth of stock

Chief Medical Officer exercised options and sold US$97k worth of stock

Price target decreased to US$44.50

Applied Therapeutics Grants Fast Track Designation by FDA for AT-007 for Galactosemia

Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder

CFO & Head of Business Development recently sold US$108k worth of stock

Chief Commercial Officer recently sold US$53k worth of stock

Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Independent Director exercised options to buy US$1.6m worth of stock.

New 90-day low: US$18.92

Chief Medical Officer exercised options and sold US$86k worth of stock

Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)

Independent Director recently bought US$149k worth of stock

How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?

Applied Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $69 million.

Chief Medical Officer notifies of intention to sell stock

Applied Therapeutics, Inc. Announces Restart of Pediatric Galactosemia Study

Applied Therapeutics to resume galactosemia study for AT-007

New 90-day high: US$25.41

Chief Medical Officer exercised options and sold US$360k worth of stock

Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study

Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling

Price target lowered to US$53.50

Applied Therapeutics EPS misses by $0.21

New 90-day low: US$18.18

Price target raised to US$60.50

FDA Grants At-007 Pediatric Rare Disease Designation and Orphan Designation for Treatment of PMM2-CDG

New 90-day low: US$22.43

Applied Therapeutics to Present Data on AT-001 for Treatment of Diabetic Cardiomyopathy at Annual Meeting of the European Association for the Study of Diabetes

New 90-day low - US$24.69

Applied Therapeutics, Inc. announced that it has received $27.158092 million in funding

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell Microcap Value Index

Applied Therapeutics, Inc.(NasdaqGM:APLT) dropped from Russell Microcap Index

Earnings and Revenue History

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies